Q-omics provides the consensus-scored TMEM61 profile across patient tissues and cancer cell-line models. TMEM61 expression is associated with patient survival in 28 of 34 cancer types, with the highest sampling consensus in CESC. Among the 18 cancer types available for tumor–normal comparison, TMEM61 is differentially expressed in 14, with the highest sampling consensus in KIRC. Additionally, TMEM61 RNA expression shows 12,398 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight CESC, KIRC, and THYM as cancer lineages where TMEM61 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TMEM61 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TMEM61 survival associations across molecular data types. TMEM61 RNA expression shows survival associations in the most cancer types (28), followed by mutation status (8). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TMEM61 RNA expression–survival associations across cancer types. High TMEM61 expression shows unfavorable associations in CESC, LGG, LUSC, UVM and BLCA, but favorable associations in COAD. The CESC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify CESC as the clearest survival context for TMEM61 RNA expression.
This table summarizes TMEM61 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for TMEM61. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TMEM61 shows lower tumor expression in KIRC, KIRP, COAD, LUSC and HNSC and higher tumor expression in LUAD. The KIRC box plot shows higher TMEM61 RNA expression in normal versus tumor tissue (log2 FC = −3.827, t-test p < 0.001).
This table shows molecular features associated with TMEM61 in patient tissues and cancer cell lines. In patient samples, TMEM61 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, TMEM61 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Leukemia, while CRISPR and shRNA rows add functional-dependency signals in SOFT_TISSUE and LUNG_SCLC.
